Tissue Diagnostic Market
Global Tissue Diagnostic market is valued at USD 3831.90 Million in 2022 and is projected to reach a value of USD 6107.47 Million by 2030 at a CAGR of 6.00% over the forecast period. Tissue diagnostic techniques are primarily used to understand the antigens that have been stored in a particular tissue. Tissue diagnostics entails the monitoring, diagnosis, and management of various stages of cancer, most notably breast cancer, prostate cancer, and gastric cancer. The rising cancer prevalence, improved infrastructure for cancer diagnostics, rising healthcare spending, and various technological advancements in the Tissue Diagnostic field are the major factors propelling the growth and demand of the global Tissue Diagnostic market. Tissue diagnostics is emerging as a significant field of diagnostics research due to the ability of tissue samples to elucidate various aspects of various biological states. Tissue diagnostics, in particular, has played an important role in cancer diagnostics and analysis, allowing scientists and researchers to detect the presence of cancer by probing tissue samples.
In addition, various cancer screening recommendations and reimbursement of medical expenses are driving market growth. Similarly, the constant advancements in Tissue Diagnostic equipment, and increasing healthcare consciousness among the general population as well as the availability of reimbursements, are driving market growth during the forecast period. The high cost of Tissue Diagnostic instruments, low expendable income, and an unawareness concerning Tissue Diagnostic in emerging economies, on the other hand, are key factors that may hinder the target market growth.
Tissue Diagnostic Market Size, 2022 To 2030 (USD Million)
Market Segmentation of Tissue Diagnostic Market :
The global Tissue Diagnostic market is segmented on the basis of product into consumables which is further segmented to antibodies, kits, reagents, probes; and instruments which is further bifurcated to slide staining system, scanner, tissue processing system; and other instruments. Based on technology, the Tissue Diagnostic market is segmented into in-situ hybridization (ISH), immunohistochemistry (IHC), digital pathology and workflow management, and special staining. By disease, it is segmented as breast cancer, lung cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer (NSCLC), and other diseases. By end user segment, it is segmented into hospitals, research laboratories, pharmaceutical companies, contract research organizations, and other end users.
Report Coverage & Deliverables
- Real-Time Data Updates:
- Competitor Benchmarking
- Market Trends Heatmap
- Custom Research Queries
- Market Sentiment Analysis
- Demographic and Geographic Insights
Below tree is interactive. You can click the nodes to get more information.
Based on product type, the consumables segment is projected to account for considerable share in terms of revenue in the Tissue Diagnostic market
The consumables segment dominates the Tissue Diagnostic market and provides a large market share. This is mainly due to their high demand, cost-effectiveness and ease of use. The increase in reagent rental contracts is also one of the major drivers of growth in the global consumables market.
Based on technology, the immunohistochemistry is expected to grow rapidly in the Tissue Diagnostic market
Immunohistochemistry (IHC) has the highest revenue share because it is widely used in clinical research and development of cancer diagnostics and treatments. IHC is preferable over traditional enzyme staining techniques because it can distinguish between different types of cancers. During the forecast period, digital pathology is expected to expand at the fastest rate. Increasing adoption of total slide imaging (WSI) among pathologists serves as one of the key drivers of segment growth.
Based on disease, the breast cancer is expected to hold a significant share in the Tissue Diagnostic market
The rising frequency of breast cancer is one of the key causes driving this segment's rise. It is the most often diagnosed cancer in women in the United States. According to the American Cancer Society, breast cancer accounted for nearly 30% of newly diagnosed malignancies in women in 2017. As a result, rising cancer incidences, as well as improvements in the field of Tissue Diagnostic, are important factors driving market expansion over the forecast period.
In the region, the North America Tissue Diagnostic market holds significant revenue share.
The North American region is leading the Tissue Diagnostic market with the strong presence of several public programmes aimed at reducing cancer incidence and the significant need for cancer diagnosis supplements. In addition, regional expansion would be aided by access to technically advanced cancer diagnostic procedures and tools, favorable R&D activities, rising medical facilities, and government initiative for the development and implementation of innovative diagnostic platforms.
The Asia-Pacific is expected to grow at a substantial rate over the forecast period due to the surge in the number of patients suffering from chronic diseases and the growing population. According to reputable estimates, approximately 2.25 million individuals are cancer patients, in the Indian subcontinent almost more than 7 lakh people dying due to the disease.
The key players in the Tissue Diagnostic market are Roche (Switzerland), Thermo Fisher Scientific (US), Danaher (US), ABCAM (UK), Abbott (US), Merck KGAA (Germany), Agilent Technologies (US), BD (US), Qiagen (Germany), Hologic (US), Bio Rad (US), Sakura Fientek Japan (Japan), Biomeriux (France), BioSB (US), Cell Signaling Technology (US), Biogenex (US), Histoline Laboratories (Italy), Amos Scientific PTY Ltd (Australia), Slee Medical GMBH (Germany), Jinhua Yidi Medical Appliance Co. Ltd (China), Cellpath Ltd(UK), Medite GMBH (Germany), and Dipath S.P.A. (Italy).
Tissue Diagnostic Market is Segmented as Follows:
- Product (Consumables, Instruments)
- Technology (Immunohistochemistry (IHC), In Situ Hybridization (ISH), Digital Pathology and Workflow Management, Special Staining)
- Disease (Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-Small Cell Lung Cancer (NSCLC), Other Diseases)
- End User (Hospitals, Research Laboratories, Pharmaceutical Companies, Contract Research Organizations, Other End Users)
|Regions & Countries Covered
- North America - (U.S., Canada, Mexico)
- Europe - (U.K., France, Germany, Italy, Spain, Rest Of Europe)
- Asia Pacific - (China, Japan, India, South Korea, South East Asia, Rest Of Asia Pacific)
- Latin America - (Brazil, Argentina, Rest Of Latin America)
- Middle East & Africa - (GCC Countries, South Africa, Rest Of Middle East & Africa)
- Roche (Switzerland)
- Danaher (US)
- Thermo Fisher Scientific (US)
- Abbott (US)
- Agilent Technologies (US)
- ABCAM (UK)
- Merck KGAA (Germany)
- BD (US)
- Hologic (US)
- Qiagen (Germany)
- Bio Rad (US)
- Biomeriux (France)
- Sakura Fientek Japan (Japan)
- BioSB (US)
- Biogenex (US)
- Cell Signaling Technology (US)
- Histoline Laboratories (Italy)
- Slee Medical GMBH (Germany)
- Amos Scientific PTY Ltd (Australia)
- Jinhua Yidi Medical Appliance Co.Ltd (China)
- Medite GMBH (Germany)
- Cellpath Ltd(UK)
- Dipath S.P.A. (Italy).
||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST
analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market
attractiveness analysis by segments and North America, company market share analysis, and COVID-19
Pricing and purchase options
||Avail of customized purchase options to meet your exact research needs. Explore purchase options
Tissue Diagnostic Market is Tabulated as Follows: